IDXG · Interpace Biosciences, Inc. · Executive Compensation
Market Cap
$42.19M
Shares
5.54M
Volume · Feb 25
186.4K
Avg daily vol (3M)
—
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Robert Gorman | director | Resigned | 2023-12-12 |
| Robert Gorman | Chairman of the Board | Resigned | 2023-12-12 |
| Edward Chan | Class II director | Resigned | 2023-11-16 |
| Christopher McCarthy | Chief Financial Officer | Appointed | 2023-08-02 |
| Christopher McCarthy | Principal Financial Officer | Appointed | 2023-04-25 |
| Stephen J. Sullivan | Class I director | Appointed | 2022-11-15 |
| Thomas Freeburg | Chief Financial Officer | Resigned | 2022-10-04 |
Leadership
- Thomas Burnell CEO
- Thomas W. Burnell CEO, Board Member
- Christopher McCarthy CFO
- Thomas J. Freeburg CFO
- Dr. Vijay Aggarwal Board Member
- Eric Lev Board Member
- Fortunato Ron Rocca Board Member
- Jack E. Stover Board Member
- Joseph Keegan, PhD Board Member
- Ron Rocca Board Member
- Stephen J. Sullivan Board Member